Large B-cell lymphoma of the leg: Clinical and pathologic characteristics in a North American series

被引:21
作者
Brogan, BL
Zic, JA
Kinney, MC
Hu, JY
Hamilton, KS
Greer, JP
机构
[1] Vanderbilt Univ, Sch Med, Dept Med Dermatol & Oncol, Nashville, TN 37212 USA
[2] Vanderbilt Univ, Sch Med, Dept Pathol, Nashville, TN 37212 USA
[3] Univ Texas, Hlth Sci Ctr, Dept Pathol Hematopathol, San Antonio, TX USA
[4] E Tennessee State Univ, Dept Med, Johnson City, TN 37614 USA
关键词
D O I
10.1067/S0190-9622(03)00889-2
中图分类号
R75 [皮肤病学与性病学];
学科分类号
100206 ;
摘要
Background: Large B-cell lymphoma (LBCL) of the leg is an uncommon subset of primary cutaneous B-cell lymphoma that has been described in a series of European patients. Objective. Our purpose was to evaluate the clinical manifestation, diagnostic histopathology, immunophenotype, clinical course, and response to treatment of LBCL of the leg. Methods: We conducted a retrospective case series of 3 patients with primary LBCL of the leg. Results: The 3 elderly patients presented with progressive crythematous nodules on bilateral or unilateral lower extremities. All 3 patients had pre-existing peripheral edema or peripheral vascular disease. Histopathologic examination of the nodules showed dense lymphocytic infiltrates composed predominantly of large dysplastic lymphocytes that marked as B cells (CD20(+)). In 2 cases, the neoplastic cells were BCL-2 positive. All patients responded to initial therapy with localized electron beam radiation and chemotherapy but had disease progression. One patient had a complete and durable second response to anti-CD20 monoclonal antibody (rituximab). Conclusions: The patients described have similar clinical and histopathologic features to those previously described. There may be an association between LBCL and pre-existing lower-extremity vascular disease. Treatment of LBCL is difficult, but 1 patient responded well to systemic anti-CD20 monoclonal antibody.
引用
收藏
页码:223 / 228
页数:6
相关论文
共 27 条
[1]   Treatment of multifocal primary cutaneous B-cell lymphoma: A clinical follow-up study of 29 patients [J].
Bekkenk, MW ;
Vermeer, MH ;
Geerts, ML ;
Noordijk, EM ;
Heule, F ;
Vader, PCV ;
van Vloten, WA ;
Meijer, CJLM ;
Willemze, R .
JOURNAL OF CLINICAL ONCOLOGY, 1999, 17 (08) :2471-2478
[2]   Relation between expression of adhesion molecules and clinical behavior in cutaneous follicle center cell lymphomas [J].
Beljaards, RC ;
VanBeek, P ;
Willemze, R .
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 1997, 37 (01) :34-40
[3]   Cutaneous lymphoma - Understanding the new classification schemes [J].
Duncan, LM .
DERMATOLOGIC CLINICS, 1999, 17 (03) :569-+
[4]  
Fang JM, 1999, MODERN PATHOL, V12, P295
[5]   Primary cutaneous large B-cell lymphoma -: The relation between morphology, clinical presentation, immunohistochemical markers, and survival [J].
Fernández-Vázquez, A ;
Rodríguez-Peralto, JL ;
Martínez, MA ;
Platón, EM ;
Algara, P ;
Camacho, FI ;
López-Ríos, F ;
Zarco, C ;
Sánchez-Yus, E ;
Fresno, MF ;
Barthe, L ;
Aliaga, A ;
Fraga, M ;
Forteza, J ;
Oliva, H ;
Piris, MA .
AMERICAN JOURNAL OF SURGICAL PATHOLOGY, 2001, 25 (03) :307-315
[6]  
Gascoyne RD, 1997, BLOOD, V90, P244
[7]   bcl-2 protein expression in primary cutaneous large B-cell lymphoma is site-related [J].
Geelen, FAMJ ;
Vermeer, MH ;
Meijer, CJLM ;
Van der Putte, SCJ ;
Kerkhof, E ;
Kluin, PM ;
Willemze, R .
JOURNAL OF CLINICAL ONCOLOGY, 1998, 16 (06) :2080-2085
[8]   Primary cutaneous follicle center cell lymphomas and large B cell lymphomas of the leg descend from germinal center cells. A single cell polymerase chain reaction analysis [J].
Gellrich, S ;
Rutz, S ;
Golembowski, S ;
Jacobs, C ;
von Zimmermann, M ;
Lorenz, P ;
Audring, H ;
Muche, M ;
Sterry, W ;
Jahn, S .
JOURNAL OF INVESTIGATIVE DERMATOLOGY, 2001, 117 (06) :1512-1520
[9]  
Grange F, 1999, BLOOD, V93, P3637
[10]   Intralesional therapy with anti-CD20 monoclonal antibody rituximab in primary cutaneous B-cell lymphoma [J].
Heinzerling, L ;
Dummer, R ;
Kempf, W ;
Schmid, MH ;
Burg, G .
ARCHIVES OF DERMATOLOGY, 2000, 136 (03) :374-378